{"title":"Interdisciplinary versus Multidisciplinary Pain Management","authors":"S. Russell","doi":"10.1300/J088V01N02_06","DOIUrl":"https://doi.org/10.1300/J088V01N02_06","url":null,"abstract":"","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123898427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Reinventing of the Agency for Health Care Policy and Research (AHCPR)","authors":"A. Lipman","doi":"10.1300/J088V05N02_01","DOIUrl":"https://doi.org/10.1300/J088V05N02_01","url":null,"abstract":"","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123350064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prescribing Controlled Substances for Cancer Pain","authors":"D. Robinson","doi":"10.1300/J088V01N01_08","DOIUrl":"https://doi.org/10.1300/J088V01N01_08","url":null,"abstract":"","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128175252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Call for More Evidence-Based Pharmacotherapy","authors":"A. Lipman","doi":"10.1300/J088V07N02_02","DOIUrl":"https://doi.org/10.1300/J088V07N02_02","url":null,"abstract":"","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130221159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chemotherapy-Induced Nausea and Vomiting","authors":"K. M. Diener","doi":"10.1300/J088V06N04_03","DOIUrl":"https://doi.org/10.1300/J088V06N04_03","url":null,"abstract":"Chemotherapy-induced nausea and vomiting (CINV) impacts patient with cancer who are currently receiving chemotherapy. Risk factors identifying patients most likely to suffer from CINV are summarized. The pathophysiology of CINV is reviewed to provide rationale for recommending combination antiemetic therapy to optimally control CINV. The three phases of CINV, acute, delayed and anticipatory, are discussed including treatment recommendations for each phase. Studies assessing effective antiemetic regimen for control of acute CINV are summarized providing rationale for recommendations for the use of 5HT3-receptor antagonists in this population. Control of delayed CINV is controversial. Use of combinations of metoclopramide/dexamethasone is considered standard care. However, specific subsets of patients benefit from prolonged administration of 5HT3-receptor antagonists. Increased cost of 5HT3-receptor antagonists compared to traditional antiemetics is offset by increased efficacy and decreased adverse effects...","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134594129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Double Blind, Randomized Study of Short versus Long Acting Ibuprofen Using a Dental Pain Model","authors":"H. Bauduin, J. Famaey","doi":"10.1300/J088V02N01_02","DOIUrl":"https://doi.org/10.1300/J088V02N01_02","url":null,"abstract":"The nociceptive threshold of the upper front teeth of twelve healthy volunteers was determined by an electrical stimulus delivered by a pulp tester. A single 600 mg analgesic dose of ibuprofen was administered orally either as a standard oral tablet formulation (Nerofen®) or a sustained release oral tablet formulation (Ibuslow®) in a double-blind randomized trial one week apart. The threshold was recorded at regular intervals for 24 hours following each dose. The mean baseline threshold significantly increased after 1 hour and reached its maximum after 1.5 to 2 hours for both formulations, but the height of the peak was significantly higher with the sustained-release formulation. The effect decreased and lost its significance after 4 hours for the standard formulation of ibuprofen, while the decrease was much slower with the sustained release formulation. With (he latter, 72 ± 6.5% of the effect was still present after 12 hours and a persistent, significant effect was still observed after 24 hours. This c...","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"194 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134090896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacists' Attitudes and Dispensing Patterns for Opioids in Cancer Pain Management","authors":"L. Bressler, M. Geraci, W. Feinberg","doi":"10.1300/J088V03N02_02","DOIUrl":"https://doi.org/10.1300/J088V03N02_02","url":null,"abstract":"Five hundred surveys were sent to pharmacists throughout the United States. The response rate was 33% and represented pharmacists from 24 states and the District of Columbia. Respondents answered questions describing their willingness to fill a “prescription” for 300 morphine tablets for a patient with cancer pain, under a variety of conditions. In addition, several questions on the survey were designed to assess knowledge of the clinical use of opioids. The results indicate that availability of opioids for cancer pain is limited, at least in some areas. Some respondents also displayed gaps in their knowledge of the clinical use of opioids. Seventy-nine percent of the pharmacists thought that patients taking 150 mg morphine sustained release tablets every twelve hours would become “addicts” if they continued taking this dose, little difference existed among responses from pharmacists in urban, suburban, and rural areas.","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132959465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dehydroepiandrosterone (DHEA) in Aging, Disease Modification, and Symptom Control","authors":"Laura Shane-McWhorter","doi":"10.1300/J088V06N02_02","DOIUrl":"https://doi.org/10.1300/J088V06N02_02","url":null,"abstract":"Dehydroepiandrosterone (DHEA) is a substance that has aroused great public interest in the last few years. Its sale was banned by the FDA in 1985, but the Dietary Supplement Health and Education Act (DSHEA) of 1994 allowed its return to the market, providing that it is labeled as a dietary supplement. More than 5,000 articles have been written about this hormone, although its mechanism of action and biologic activity have not been completely elucidated. Epidemiologic information indicates that DHEA levels decline with aging, and with the occurrence of other disease states such as cardiovascular disease, HIV infection, cancer, diabetes, and osteoporosis. Several of its potential beneficial effects have been shown in animals, but not in humans. There are several ongoing trials to assess its effects in a variety of diseases, such as systemic lupus erythematosus (SLE), HIV infection, and Alzheimer's disease. One of the major reasons for its popularity has been its purported anti-aging effects.","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"13 10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134466566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Assisted Suicide and Euthanasia: Cases and Commentaries","authors":"S. Valente, J. Saunders, John S Rozel","doi":"10.1300/J088V04N01-2_07","DOIUrl":"https://doi.org/10.1300/J088V04N01-2_07","url":null,"abstract":"","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"106 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115768426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Melatonin: Historical and Clinical Perspectives","authors":"Suzanne Goeser, J. Ruble, Linda Chandler","doi":"10.1300/J088V05N01_04","DOIUrl":"https://doi.org/10.1300/J088V05N01_04","url":null,"abstract":"Melatonin has gained attention as the “cure-all” of the nineties. Proponents claim uses ranging from alleviation of jet lag to cure of cancer. Although melatonin was first identified over 38 years ago, only recently has its therapeutic potential been investigated. Unfortunately, few clinical data are available to define the pharmacotherapeutic role of melatonin. As the demand for melatonin increases, so too does the need for objective, controlled clinical data. Health care professionals are obliged to review the available data prior to use in patient care.","PeriodicalId":268184,"journal":{"name":"Journal of Pharmaceutical Care in Pain & Symptom Control","volume":"104 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115799881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}